Subscribe to Newsletter
Subspecialties Oncology

Demystifying Metastasis

The ability to predict which patients will develop metastatic disease, and where, would undoubtedly be a huge coup for oncology – but much of metastasis still remains a mystery. A common theory is that tumor cells dictate metastasis, but a recent study published in Nature, shows that this may be a misconception.

“Tumor cells only indirectly influence metastasis. The tumors are excreting exosomes, and these are preparing future sites of metastasis, not the cells, so this is very different from the accepted dogma,” says co-author of the Nature paper (1), David Lyden.

Lyden and his colleagues found that tumor-excreted exosomes have distinct expression patterns of integrins, and it appears that the exosomes prepare organs to host tumor cells, by causing responses such as inflammation and vascularization, forming a metastatic niche (see Figures 1 and 2). They looked at 10 tumor cell lines which usually metastasize to specific organs – for example, pancreatic cancer often spreads to the liver – and analyzed the proteins being expressed by the cancer exosomes. Analysis showed that they could link the expression of different integrin proteins with metastatic disease in the lung, liver and brain (see Table 1).

Figure 1. Electron microscopy of mice lung section. Exosomes derived from lung tropic cancer cell are labeled with dye (appearing here as black dots).

Figure 2. Dye labelled tropic exosomes, localized in a mouse lung.

Table 1. Integrin expression profiles were linked with future metastasis in specific organs.
Integrin(s) Associated With
ITGα 6, ITGβ 4, and ITGβ 1 Lung Metastasis
ITGβ 5 Liver Metastasis
ITGβ 3 Brain Metastasis

Now, the team plan to continue their research in a larger study group, looking at different organs, and different patients, in order to further understand how metastasis works. They have a particular interest in bone cancer, as they found that patients with this secondary cancer had no integrin expression.

“Our work illustrates that we can now do a very easy blood test and predict who will develop metastatic disease, and importantly to what organ they will metastasis to. So this is really changing our traditional way of treating metastasis. We can potentially start treatment much earlier, and make a bigger impact,” says Lyden.

“This study could in the future also be applied to be used for follow-up of the patients after surgery or chemotherapy. Importantly, our work shows that preparation of future metastasis sites by the exosomes starts long before the cancer cells arrive – they indicate the true start of metastasis,” adds the study’s first author, Ayuko Hoshino.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. A Hoshino et al., “Tumor exosome integrins determine organotropic metastasis”, Nature, 527, 329–335 (2015). PMID: 26524530.
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Related Application Notes
Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

| Contributed by Agilent

Comprehensive Genomic Profiling with SureSelect Cancer CGP Assay

| Contributed by Agilent

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register